ANAPTYSBIO, INC 8-K

What Happened AnaptysBio, Inc. announced that its Board approved changing the company’s fiscal year-end from December 31 to June 30, effective with the next fiscal year beginning July 1, 2026. The Board action was taken on May 18, 2026 and reported in an 8-K filed May 21, 2026. The company plans to file a transition report on Form 10-KT covering the six-month period January 1, 2026 through June 30, 2026, and will resume quarterly reporting under the new fiscal year beginning with the quarter ending September 30, 2026. The filing was signed by Christopher M. Murphy, Chief Financial Officer.

Key Details

• Board approved change on May 18, 2026; 8-K filed May 21, 2026.
• Fiscal year-end changed from December 31 to June 30; new fiscal year starts July 1, 2026.
• Company will file a Form 10-KT for the transition period Jan 1–Jun 30, 2026.
• Quarterly reports will follow the new fiscal calendar beginning with the quarter ending Sept 30, 2026.

Why It Matters This change affects the timing and comparability of AnaptysBio’s financial reporting—investors will see a six-month transition reporting period (Jan–Jun 2026) instead of a full 12‑month fiscal year. Expect differences in how quarterly results, year‑over‑year revenue and earnings comparisons, and annual disclosures are presented during the transition. The filing does not disclose operational or management changes; it only describes the reporting calendar adjustment.